BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37185400)

  • 1. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China.
    Lin X; Chen C; Jiang T; Ma J; Huang L; Huang L; Lei H; Tong Y; Huang G; Mao X; Sun P
    Curr Oncol; 2023 Mar; 30(4):3787-3799. PubMed ID: 37185400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
    Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
    Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study.
    Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
    Front Endocrinol (Lausanne); 2022; 13():942412. PubMed ID: 36133303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
    Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
    Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus.
    Tang M; Wei XH; Cao H; Zhen Q; Liu F; Wang YF; Fan NG; Peng YD
    Front Endocrinol (Lausanne); 2022; 13():935980. PubMed ID: 35979441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.
    Fan J; Luo S; Ye Y; Ju J; Zhang Z; Liu L; Yang J; Xia M
    Nutr Metab (Lond); 2021 Sep; 18(1):82. PubMed ID: 34496912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.
    Morieri ML; Vitturi N; Avogaro A; Targher G; Fadini GP;
    J Endocrinol Invest; 2021 Sep; 44(9):1879-1889. PubMed ID: 33432553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    Guo B; Guo Y; Nima Q; Feng Y; Wang Z; Lu R; Baimayangji ; Ma Y; Zhou J; Xu H; Chen L; Chen G; Li S; Tong H; Ding X; Zhao X;
    J Hepatol; 2022 Mar; 76(3):518-525. PubMed ID: 34883157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
    Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
    Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residential greenness associated with decreased risk of metabolic- dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study.
    Chen L; Jia Y; Guo Y; Chen G; Ciren Z; Chen H; Duoji Z; Xu J; Yang T; Xu H; Feng S; Jiang Y; Guo B; Meng Q; Zhao X
    Ecotoxicol Environ Saf; 2023 Jan; 249():114338. PubMed ID: 36508840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
    Li H; Zhang Y; Luo H; Lin R
    Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China.
    Wei JY; Xu Z; Li H; Du WQ; Niu BL; Li S; Tian S; Wu J; Chen YL; Li X; Liu ZL; Xiao J; Ren GS; Ran L; Kong LQ
    Int J Med Sci; 2021; 18(14):3082-3089. PubMed ID: 34400878
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at menarche and metabolic dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study in Southwest China.
    Li K; Yin J; Qin Z; Ma B; He R; Zhuoma D; Wang Z; Liu Q; Zhao X
    Prev Med; 2023 Dec; 177():107776. PubMed ID: 37951543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes.
    Mantovani A; Csermely A; Taverna A; Cappelli D; Benfari G; Bonapace S; Byrne CD; Targher G
    Diabetes Metab; 2023 Mar; 49(2):101416. PubMed ID: 36586476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between self-reported snoring and metabolic-associated fatty liver disease: A cross-sectional analysis of the NHANES 2017-2018.
    Wang Y; Shen R; Ge J
    Sleep Med; 2023 Jan; 101():414-420. PubMed ID: 36516525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: A retrospective case-control study.
    Liu J; Duan S; Wang C; Wang Y; Peng H; Niu Z; Yao S
    Front Endocrinol (Lausanne); 2022; 13():1035418. PubMed ID: 36531447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.